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Pharmacokinetic drug interaction studies performed
during the drug development process, or post-licensing
p r o v i d et h es u b s t a n t i v ed a t ab a s ef r o mw h i c hr e c o m -
mendations regarding the use of certain drug combina-
tions are made. However given the sheer number of
potential interactions, especially in the context of an
ageing population with inevitable co-morbidities and
polypharmacy, we need to be able to make informed
decisions even in the absence of study data. Thus
knowledge of drug handling (the role of various meta-
bolic enzymes and transporters etc.) is essential so that
pre-clinical data (determining whether the drug is a sub-
strate or an inhibitor of a particular enzyme or transpor-
ter; use of in vitro/in vivo extrapolation tools etc.) can
be the basis for deciding how to proceed. However we
also need to appreciate that with the ageing process
drug absorption and clearance can alter so the challenge
then is to understand how this may impact on the mag-
nitude of a drug-drug interaction. While the major
f o c u si nt h eH I Vf i e l dh a sb e e no nC Y P 4 5 0e n z y m e s
(for the obvious reason that many of the drugs are
extensively metabolised and/or are inducers/inhibitors)
there is a growing awareness of the key role for other
proteins - in particular UDP-glucuronyltransferases
(UGTs) and transporters (ABC transporters such as P-
gp, MRPs; SLCO transporters such as OATP1B1, OCTs,
OATs). This is a rapidly emerging field and one which
is going to impact on our understanding of mechanisms
of drug-drug interactions. In addition the variable
expression of enzymes and transporters due to pharma-
cogenetic changes is another important consideration.
Unexpected interactions will continue to emerge and
will need to be managed. Ultimately the key to manage-
ment of patients on multiple drugs is clinical vigilance,
access to adequate resources to help inform (e.g. web
based resources), and in some cases the careful use of
therapeutic drug monitoring.
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